Buchumschlag

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

Multiple myeloma (MM) is still a fatal plasma cell cancer. Novel compounds are currently clinically tested as a single agent in relapsing patients, but in best cases with partial response of a fraction of patients, emphasising the need to design tools predicting drug efficacy. Histone deacetylase in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Moreaux, Jérôme (VerfasserIn) , Reme, T. (VerfasserIn) , Leonard, W. (VerfasserIn) , Veyrune, J.-L. (VerfasserIn) , Requirand, G. (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn) , Hose, Dirk (VerfasserIn) , Klein, B. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 18 July 2013
In: British journal of cancer
Year: 2013, Jahrgang: 109, Heft: 3, Pages: 676-685
ISSN:1532-1827
DOI:10.1038/bjc.2013.392
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bjc.2013.392
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bjc2013392
Volltext
Verfasserangaben:J. Moreaux, T. Reme, W. Leonard, J.-L. Veyrune, G. Requirand, H. Goldschmidt, D. Hose and B. Klein
Beschreibung
Zusammenfassung:Multiple myeloma (MM) is still a fatal plasma cell cancer. Novel compounds are currently clinically tested as a single agent in relapsing patients, but in best cases with partial response of a fraction of patients, emphasising the need to design tools predicting drug efficacy. Histone deacetylase inhibitors (HDACi) are anticancer agents targeting epigenetic regulation of gene expression and are in clinical development in MM.
Beschreibung:Gesehen am 07.06.2021
Beschreibung:Online Resource
ISSN:1532-1827
DOI:10.1038/bjc.2013.392

Ähnliche Einträge